Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...

Leqembi is expected to grow slowly – in part as a result of the negative hangover in sentiment that surrounded Aduhelm’s approval on controversial data, but also due to logistical hurdles ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high ...

INmune Bio’s stock plunged by more than 50% after its TNF inhibitor failed to demonstrate efficacy in Alzheimer’s patients ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

By Siddhi Mahatole and Puyaan Singh (Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve ...

(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with ...

MUSC Health's Kids Eat Free program offers free meals to children 18 and under in various locations from June 16 to July 25, ...